Cariprazine and cognition in patients with schizophrenia and bipolar disorder: A systematic review

Author:

Garcia-Fernandez LORENA1ORCID,Romero Veronica2,Peñuelas-Calvo Inmaculada3,de Mon Miguel Angel Álvarez4,Scala Mauro5,Ferreiro Carmen Romero6,López Estela Jiménez7,Santos Jose Luis8,Rodriguez-Jimenez Roberto3

Affiliation:

1. Universidad Miguel Hernandez de Elche

2. Universidad Europea: Universidad Europea de Madrid SLU

3. Complutense University of Madrid: Universidad Complutense de Madrid

4. Universidad de Alcala

5. Università di Bologna: Universita di Bologna

6. Francisco de Vitoria University: Universidad Francisco de Vitoria

7. University of Castilla-La Mancha: Universidad de Castilla-La Mancha

8. Virgen de la Luz Hospital: Hospital Virgen de la Luz

Abstract

Abstract

Background Cariprazine is a recently incorporated drug whose differential characteristic is its partial agonism for the D3 receptor, with great affinity for it, higher than dopamine itself. Preclinical studies with animal models have shown a manifest pro cognitive effect. The objective of this study is to conduct a systematic review examining the effects of cariprazine on cognitive measures in patients with schizophrenia and bipolar disorder. Methods Two independent reviewers searched PubMed, Web of Science, Scopus, and Cochrane Library databases to December 31st 2023 following the PRISM guideline. Additional studies were identified through hand-searching of references of the included studies. Eligible studies were those randomized controlled trials published in English evaluating the effects of the use of cariprazine on cognitive outcomes in patients with mental disorders. Quality assessment followed the Jadad scale recommendations. Results From a total of 136 initial reports, up to 5 studies comprising 6104 patients with schizophrenia, bipolar I mania and bipolar I depression were included in the systematic review. In patients with schizophrenia, the use of cariprazine showed better cognitive outcomes compared to placebo in both early and late stages. Furthermore, cariprazine showed cognitive advantages over risperidone in patients with a predominance of negative symptoms and over aripiprazole when the variables power and continuity of attention were measured. In patients with bipolar disorder, cariprazine showed cognitive improvements compared to placebo. Most studies seem to find a greater pro cognitive effect with low doses of cariprazine (1.5-3 mg/d). Conclusions Overall, cariprazine improved cognitive measures compared to placebo, especially in patients with greater baseline impairment and when low doses are used. Thus, the use of cariprazine in patients with schizophrenia and bipolar disorder could become an effective therapeutic option to enhance cognition as well as other inherent symptoms of both disorders. Systematic review registration PROSPERO CRD42023485028.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3